Beneficial effects of oral uridine in mitochondrial toxicity [5]

AIDS

Volumn 18, Issue 7, 2004, Pages 1085-1086

  Walker, Ulrich A ^a   Langmann, Peter ^b   Miehle, Nikolaus ^a   Zilly, Michael ^b   Klinker, Hartwig ^b   Petschner, Franziska ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE; STAVUDINE; URIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; HUMAN; LACTATE BLOOD LEVEL; LETTER; LIVER CELL; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; METABOLITE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL TOXICITY; MYALGIA; NUCLEOMAXX; PRIORITY JOURNAL; SUGARCANE; SUPPLEMENTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DIETARY SUPPLEMENTS; FATTY LIVER; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; URIDINE;

EID: 2342463067     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200404300-00025     Document Type: Letter

References (8)

1. Walker UA, Koch E, Venhoff N, Klinker H, Langman P, Zilly M, et al. Uridine prevents and treats mtDNA-depletion by NRTI-pyrimidine analogues and fully restores mitochondrial function. Antiviral Ther 2003; 8:L17.
2. Walker UA, Venhoff N, Koch E, Olschweski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antiviral Ther 2003; 8:463-470.
3. Sommadossi JP, Carlisle R, Schinazi RF, Zhou Z. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 1988; 32:997-1001.
4. Calabresi P, Falcone A, St Clair MH, Wiemann MC, Chu SH, Darnowski JW. Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity. Blood 1990; 76:2210-2215.
5. Leyva A, van Groeningen CJ, Kraal I, Gall H, Peters GJ, Lankelma J, Pinedo HM. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 1984; 44:5928-5933.
6. van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 1986; 70:745-750.
7. van Groeningen CJ, Peters GJ, Nadal JC, Laurensse E, Pinedo HM. Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 1991; 83:437-441.
8. Girot R, Hamet M, Perignon JL, Guesnu M, Fox RM, Cartier P, et al. Cellular immune deficiency in two siblings with hereditary orotic aciduria. N Engl J Med 1983; 308:700-704.